DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Cobimetinib
Cobimetinib
Oncofocus® Precision Oncology
Product Monograph Including Patient Medication Information
Quantification of Cobimetinib, Cabozantinib, Dabrafenib, Niraparib
New Oncology Reimbursements in Belgium
Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma
Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction
Cotellic, INN-Cobimetinib
Cobimetinib/Vemurafenib Combination Therapy for Melanoma: a Nursing Tool from the Melanoma Nursing Initiative (MNI)
New Century Health Policy Changes April 2021
COTELLIC™ (Cobimetinib) Oral Tablet
Oncology Orals Solid Tumors
Estimation of the Percentage of US Patients with Cancer Who Benefit from Genome‐Driven Oncology
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
Current Melanoma Treatments: Where Do We Stand?
Survival Extrapolation Approaches: New Era, New Methods?
TFS-CLI 16696 Targeted Therapies and Biomarkers Infographic
COTELLIC (Cobimetinib) RATIONALE for INCLUSION in PA PROGRAM
Treatment of Melanoma/Renal Cell Carcinoma
Top View
Breast Cancer - Invasive Jane Doe 1/15/2020
Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
Table 1: Drug-Drug Interactions of Common Cardiac Drugs and Chemotherapeutic Agents*
Molecularly Targeted Drug Combinations Demonstrate Selective Effectiveness for Myeloid- and Lymphoid- Derived Hematologic Malignancies
What's New in Immunotherapy and Targeted Therapy?
Treatment of Melanoma and Breast Cancer
3.-Igarashi-2017.JCB .Pdf
NHS Borders NHS Borders Education Centre Planning & Performance Borders General Hospital Melrose Roxburghshire TD6 9BD 01896 825545
[email protected]
Genomic Features of Exceptional Response in Vemurafenib
A Phase Ib, Open Label, Dose-Escalation Study
Results of Juvenile Animal Studies (JAS) and Impact on Anti-Cancer Medicine Development and Use in Children Project Report
Venetoclax-Based Therapies for Acute Myeloid Leukemia T ∗ Veronica A
A Monocentric Phase I Study of Vemurafenib Plus Cobimetinib Plus
5-Year Outcomes with Cobimetinib Plus Vemurafenib in BRAFV600 Mutation–
Sorafenib Sensitizes Melanoma Cells to Vemurafenib Through Ferroptosis
Roche to Share Important Oncology Data at European Cancer Congress
(Cotellic) for Metastatic Melanoma
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study